慢性腎臓病治療市場- 世界の産業規模、シェア、動向、機会、予測、製品タイプ別、エンドユーザー別、地域別、競合別、2020～2030年

慢性腎臓病治療の世界市場規模は2024年に354億米ドルとなり、2030年のCAGRは4.70%で、予測期間中に着実な成長が予測されています。

世界の慢性腎臓病（CKD）治療市場は、より広範な医療産業の重要なコンポーネントであり、CKDに罹患した患者の管理と生活の質の向上を目的とした幅広い医療介入、治療、薬剤を包含しています。CKDは進行性で無症状のことが多く、放置すると腎不全に至る可能性があります。そのため、CKD治療市場はこの世界の健康問題に対処する上で極めて重要な役割を果たしています。

市場促進要因

慢性腎臓病（CKD）と関連併存疾患の有病率の上昇

主要市場課題

経済的障壁と医療格差

主要市場動向

個別化医療と精密医療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の慢性腎臓病治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品タイプ別（診断、治療、透析、その他）
  • エンドユーザー別（病院、診断ラボ、その他）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米の慢性腎臓病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の慢性腎臓病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋の慢性腎臓病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の慢性腎臓病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの慢性腎臓病治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 製品上市
• 合併と買収

第13章 世界の慢性腎臓病治療市場：SWOT分析

第14章 競合情勢

• AbbVie Inc.
• Amgen Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Merck & Co. Inc.
• Pfizer Inc.
• Sysmex Corporation
• Teva Pharmaceutical Industries Ltd.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Chronic Kidney Disease Treatment Market was valued at USD 35.40 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 4.70% through 2030. The Global Chronic Kidney Disease (CKD) Treatment Market is a critical component of the broader healthcare industry, encompassing a wide range of medical interventions, therapies, and medications aimed at managing and improving the quality of life for individuals affected by CKD. CKD is a progressive and often asymptomatic condition that can lead to kidney failure if left untreated. As such, the CKD Treatment Market plays a pivotal role in addressing this global health concern.

Key Market Drivers

Rising Prevalence of Chronic Kidney Disease (CKD) and Related Comorbidities

The increasing global prevalence of Chronic Kidney Disease (CKD) is a fundamental driver of the Global CKD Treatment Market, as it directly fuels demand for pharmaceuticals, dialysis services, renal replacement therapies, and specialized healthcare services. This rising disease burden is largely attributed to several interconnected factors, including aging populations, lifestyle-related disorders, and genetic predispositions. Chronic Kidney Disease is a progressive and irreversible condition that affects millions worldwide. The 2023 ISN-GKHA multinational study on the global burden of kidney disease reports that approximately 850 million people worldwide are affected by Chronic Kidney Disease (CKD). The findings highlight that CKD impacts individuals across all age groups and racial backgrounds, with a disproportionately higher prevalence among economically disadvantaged populations. These insights emphasize the urgent need for targeted healthcare policies, improved access to early diagnosis, and expanded treatment infrastructure, particularly in high-risk and underserved communities, with a significant portion of cases remaining undiagnosed until the later stages. This expanding patient population is a major catalyst for the growth of the CKD treatment market. Improved screening programs and awareness campaigns are leading to earlier diagnoses, increasing demand for medications and lifestyle management interventions. Among patients without proteinuria data, the CKD diagnosis rate was 5.9%, with a significantly lower rate of 2.9% in stage G2. In contrast, for patients with quantitative proteinuria test results, the diagnosis rates were 43.5% overall and 31.3% in stage G2. These findings underscore the critical role of quantitative proteinuria testing in early CKD detection, highlighting a significant gap in diagnosis rates when such data is unavailable. This reinforces the need for wider adoption of advanced diagnostic protocols to improve CKD identification and clinical decision-making.

Key Market Challenges

Economic Barriers and Healthcare Disparities

One of the primary challenges is the economic disparity that exists globally. Access to advanced CKD treatments and medications often requires significant financial resources. High healthcare costs, including expenses related to dialysis, transplantation, and specialized medications, can be prohibitive for individuals with limited financial means.

In many regions, healthcare coverage and insurance options may not adequately address CKD treatment costs. Patients without comprehensive insurance may face difficulties in accessing essential treatments, which can lead to delayed or suboptimal care. Vulnerable populations, such as low-income individuals and underserved communities, are disproportionately affected by economic barriers. This can result in delayed CKD diagnosis, limited access to specialized care, and poorer outcomes.

Key Market Trends

Personalized Medicine and Precision Care

Personalized medicine is gaining prominence in the CKD treatment market. Healthcare providers are increasingly customizing treatment plans to meet the specific needs of individual CKD patients. This approach takes into account factors such as the patient's stage of CKD, comorbidities, genetic factors, and response to previous treatments.

Biomarker research plays a crucial role in personalizing CKD treatment. Biomarkers, such as specific proteins or genetic markers, are used to predict disease progression and treatment efficacy. This trend enables healthcare professionals to make more informed decisions about treatment strategies, including medication selection and dosing. Advances in genomics are revolutionizing CKD care. Genetic testing can identify genetic mutations or predispositions that influence CKD risk and progression. This information allows for the development of targeted therapies and interventions, with the potential to slow or halt disease progression in individuals with specific genetic profiles.

Key Market Players

• AbbVie Inc.
• Amgen Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Merck & Co. Inc.
• Pfizer Inc.
• Sysmex Corporation
• Teva Pharmaceutical Industries Ltd

Report Scope:

In this report, the Global Chronic Kidney Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Kidney Disease Treatment Market, By Product Type:

• Diagnosis
• Treatment
• Dialysis
• Others

Chronic Kidney Disease Treatment Market, By End User:

• Hospitals
• Diagnostic Laboratories
• Others

Chronic Kidney Disease Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Kidney Disease Treatment Market.

Available Customizations:

Global Chronic Kidney Disease Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chronic Kidney Disease Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Diagnosis, Treatment, Dialysis, Others)
  • 5.2.2. By End User (Hospital, Diagnostic Laboratories, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Chronic Kidney Disease Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Chronic Kidney Disease Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Chronic Kidney Disease Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Chronic Kidney Disease Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By End User

7. Europe Chronic Kidney Disease Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Chronic Kidney Disease Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By End User
  • 7.3.2. United Kingdom Chronic Kidney Disease Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By End User
  • 7.3.3. Italy Chronic Kidney Disease Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By End User
  • 7.3.4. France Chronic Kidney Disease Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Chronic Kidney Disease Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By End User

8. Asia-Pacific Chronic Kidney Disease Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By End User
• 8.2.3 By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Chronic Kidney Disease Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By End User
  • 8.3.2. India Chronic Kidney Disease Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Chronic Kidney Disease Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Chronic Kidney Disease Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Chronic Kidney Disease Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By End User

9. South America Chronic Kidney Disease Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Chronic Kidney Disease Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Chronic Kidney Disease Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Chronic Kidney Disease Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By End User

10. Middle East and Africa Chronic Kidney Disease Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Chronic Kidney Disease Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Chronic Kidney Disease Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE Chronic Kidney Disease Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Chronic Kidney Disease Treatment Market: SWOT Analysis

14. Competitive Landscape

• 14.1. AbbVie Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Amgen Inc.
• 14.3. Bayer AG
• 14.4. Bristol-Myers Squibb Company
• 14.5. F. Hoffmann-La Roche Ltd
• 14.6. GlaxoSmithKline PLC
• 14.7. Merck & Co. Inc.
• 14.8. Pfizer Inc.
• 14.9. Sysmex Corporation
• 14.10. Teva Pharmaceutical Industries Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer